Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $54.3052W HIGH $88.31
Volume
1.12 M
Value Traded
174.78 M
Short % Float
13.03%
+0.33%Week
-14.72%1 Month
-23.5%3 Month
-5.71%6 Month
+233.8%5 Year
-14.51%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
7.83 B
EPS (TTM)
-6.43
P/E Ratio
-
Ent. Value
6.40 B
Total Shares
124.43 M
Float Shares
134.15 M
Insiders
3.51%
Institutions
113.23%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
CYTK Catalyst Timeline
Dated clinical, regulatory and corporate events for Cytokinetics, Incorporated
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cytokinetics, Incorporated
1204Total events
15Upcoming
269Tier-1 (high impact)
2015 to 2026Coverage
Upcoming catalysts 2
Event history 50
●Trial InitiationMYQORZOApprovedTrial
Cytokinetics announces start of ASPEN-HCM real-world study of MYQORZO in oHCM
symptomatic obstructive hypertrophic cardiomyopathy (oHCM)source ↗
▲Grant / FundingCorporate
Cytokinetics opens applications for ninth annual Communications Grant Program
hypertrophic cardiomyopathy (HCM) and heart failuresource ↗
▲Oral PresentationAficamtenApprovedPresentation
Additional results from ACACIA-HCM presented at ESC Congress 2026
non-obstructive hypertrophic cardiomyopathysource ↗
▲PublicationAficamtenApprovedPresentation
MAPLE-HCM post-hoc analysis published in JACC: Heart Failure
obstructive hypertrophic cardiomyopathysource ↗
▲Oral PresentationAficamtenApprovedPresentation
ACACIA-HCM results presented in Hot Line Session at ESC Congress 2026
non-obstructive hypertrophic cardiomyopathysource ↗
▲Primary Endpoint MetAficamtenApprovedClinical Data
ACACIA-HCM met both dual primary endpoints
non-obstructive hypertrophic cardiomyopathysource ↗
▲PublicationAficamtenApprovedPresentation
ACACIA-HCM results published in The New England Journal of Medicine
non-obstructive hypertrophic cardiomyopathysource ↗
▲Secondary Endpoint DataAficamtenApprovedClinical Data
Key ranked secondary endpoints met; some not met
non-obstructive hypertrophic cardiomyopathysource ↗
▲Full ResultsAficamtenApprovedClinical Data
Global efficacy analysis presented and published in Circulation
non-obstructive hypertrophic cardiomyopathysource ↗
▲Additional DataAficamtenApprovedClinical Data
Global efficacy analysis presented
non-obstructive hypertrophic cardiomyopathysource ↗
▲MHRA MilestoneMYQORZOApprovedEx-US Regulatory
MHRA granted marketing authorisation for MYQORZO (aficamten) in the UK
symptomatic obstructive hypertrophic cardiomyopathysource ↗
▲Other Regulator MilestoneAficamtenApprovedEx-US Regulatory
NICE issued positive guidance recommending aficamten for use in England and Wales
symptomatic obstructive hypertrophic cardiomyopathysource ↗
◆Oral PresentationPresentation
Cytokinetics management to participate in Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
◆Oral PresentationPresentation
Cytokinetics management to participate in Jefferies Global Healthcare Conference fireside chat
▲Product LaunchMYQORZOApprovedPost-Market
First commercial European launch of MYQORZO (aficamten) in Germany
symptomatic obstructive hypertrophic cardiomyopathy (oHCM)source ↗
◆Oral PresentationPresentation
Third Annual Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB)
▲Topline ReadoutAficamtenApprovedClinical Data
Positive topline results in ACACIA-HCM trial
non-obstructive HCMsource ↗
◆Oral PresentationPresentation
Cytokinetics management to participate in fireside chat at 2026 RBC Capital Markets Global Healthcare Conference
◆Oral PresentationMYQORZOApprovedPresentation
Dose-dependent effects of aficamten compared with metoprolol in obstructive HCM: the MAPLE-HCM study
obstructive hypertrophic cardiomyopathysource ↗
▲Full ResultsMYQORZOApprovedClinical Data
Dose-dependent analysis shows MYQORZO outperforms metoprolol across sex and doses
obstructive hypertrophic cardiomyopathysource ↗
▲Full ResultsAficamtenApprovedClinical Data
Open-label extension study in Chinese patients shows aficamten well tolerated through 48 weeks
obstructive hypertrophic cardiomyopathysource ↗
◆Poster PresentationPresentation
Real-world evidence presentations on HCM burden at ESC Heart Failure 2026
hypertrophic cardiomyopathysource ↗
◆Oral PresentationAficamtenApprovedPresentation
Dose-dependent effects of aficamten compared with metoprolol in obstructive HCM: the MAPLE-HCM study
obstructive hypertrophic cardiomyopathysource ↗
◆Poster PresentationAficamtenApprovedPresentation
No Increase in Arrhythmia Burden Following Aficamten Treatment in Obstructive Hypertrophic Cardiomyopathy: Extended Ambulatory Electrocardiogram Analysis From FOREST-HCM
obstructive hypertrophic cardiomyopathysource ↗
◆Poster PresentationMYQORZOApprovedPresentation
No Increase in Arrhythmia Burden Following Aficamten Treatment in Obstructive Hypertrophic Cardiomyopathy: Extended Ambulatory Electrocardiogram Analysis From FOREST-HCM
obstructive hypertrophic cardiomyopathysource ↗
◆Oral PresentationAficamtenApprovedPresentation
Effect of Aficamten Compared with Metoprolol in Women Versus Men: Analysis of MAPLE-HCM
obstructive hypertrophic cardiomyopathysource ↗
◆Oral Presentationomecamtiv mecarbilFiledPresentation
The Influence of QRS Duration and Resynchronization Status on the Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure with Reduced Ejection Fraction: The GALACTIC-HF Trial
heart failure with reduced ejection fractionsource ↗
◆Poster PresentationPresentation
Impact of Guideline-Directed Medical Therapies on Clinical and Economic Outcomes in Nonobstructive Hypertrophic Cardiomyopathy: Analysis of Data from a Multinational Cross-Sectional Survey
nonobstructive hypertrophic cardiomyopathysource ↗
◆Oral PresentationMYQORZOApprovedPresentation
Effect of Aficamten Compared with Metoprolol in Women Versus Men: Analysis of MAPLE-HCM
obstructive hypertrophic cardiomyopathysource ↗
◆Oral PresentationAficamtenApprovedPresentation
Favorable Effect of Aficamten on Left Atrial Mechanics in Obstructive Hypertrophic Cardiomyopathy: Insights From the SEQUOIA-HCM Trial
obstructive hypertrophic cardiomyopathysource ↗
◆Poster PresentationPresentation
Impact of Hypertrophic Cardiomyopathy on Work Productivity and Activity Impairment in Patients with HCM: Analysis of a Real-World Cross-Sectional Survey
hypertrophic cardiomyopathysource ↗
◆Oral PresentationMYQORZOApprovedPresentation
Favorable Effect of Aficamten on Left Atrial Mechanics in Obstructive Hypertrophic Cardiomyopathy: Insights From the SEQUOIA-HCM Trial
obstructive hypertrophic cardiomyopathysource ↗
▼Equity OfferingCorporate
Closing of public offering of common stock with full exercise of underwriters' option for gross proceeds of $805 million
▼Equity OfferingCorporate
Pricing of upsized public offering of common stock at $71.00 per share
▲FDA ApprovalMYQORZOApprovedFDA Decision
MYQORZO approved by European Commission for adults with symptomatic obstructive HCM
symptomatic obstructive hypertrophic cardiomyopathysource ↗
▲FDA Filing AcceptedMYQORZOApprovedRegulatory Filing
sNDA for MAPLE-HCM accepted for filing by FDA
obstructive HCM (MAPLE-HCM)source ↗
▲Topline ReadoutAficamtenApprovedClinical Data
ACACIA-HCM met dual primary endpoints of KCCQ and maximal exercise performance
non-obstructive hypertrophic cardiomyopathysource ↗
▼Equity OfferingCorporate
Proposed public offering of common stock for approximately $650 million
◆Topline ReadoutAficamtenApprovedClinical Data
Topline results from ACACIA-HCM
Non-Obstructive Hypertrophic Cardiomyopathysource ↗
◆Oral PresentationAficamtenApprovedPresentation
Conference call to discuss ACACIA-HCM topline results
Non-Obstructive Hypertrophic Cardiomyopathysource ↗
▲Primary Endpoint MetAficamtenApprovedClinical Data
ACACIA-HCM met dual primary endpoints KCCQ-CSS and pVO2
non-obstructive hypertrophic cardiomyopathysource ↗
▲Secondary Endpoint DataAficamtenApprovedClinical Data
Key secondary endpoints met: NYHA class, composite z-score, NT-proBNP
non-obstructive hypertrophic cardiomyopathysource ↗
▲FDA ApprovalMYQORZOApprovedFDA Decision
MYQORZO approved in US, China, and EU for oHCM
obstructive hypertrophic cardiomyopathy (oHCM)source ↗
◆Enrollment UpdateAficamtenApprovedTrial
CEDAR-HCM (pediatric oHCM) enrolling
pediatric obstructive hypertrophic cardiomyopathy (oHCM)source ↗
◆Trial Initiationomecamtiv mecarbilFiledTrial
COMET-HF (Phase 3 confirmatory trial of omecamtiv mecarbil) enrolling
heart failure with reduced ejection fraction (HFrEF)source ↗
◆Trial InitiationulacamtenTrial
AMBER-HFpEF (Phase 2 trial of ulacamten) enrolling
heart failure with preserved ejection fraction (HFpEF)source ↗
Past FDA Catalysts and PDUFA Decisions
How CYTK actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | Aficamten (investigational cardiac myosin inhibitor) | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C58 / 100
Pipeline Score
$2.5B
Pipeline Value
$294M
Commercial Value
Richly Valued
Valuation Signal
5
Drugs Scored
0.3x
rNPV / MCap
Top 8%
Small Cap(rank 54 of 660)
Percentile Rank
Cytokinetics, Incorporated carries a moderate pipeline score (58/100), with $3.8B risk-adjusted pipeline value, led by Omecamtiv mecarbil in Heart Failure (Phase 3), across $61B in total addressable markets.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $67.7M x 4.4 = $294M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| MYQORZO | $30M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Omecamtiv mecarbil Small moleculeNCT01380223 | Heart Failure | Phase 3 | COMPLETED | 10,705 | Apr 1, 2006 |
Clinical Trial Results
Readouts, endpoints and source filings for every CYTK program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Malik Fady IbrahamOfficer (EVP Research & Development) | Option | 3,500 157,402 held | $7.80 | 10/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CYTK
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 3.8 % (72.7 %) | 425.95 M | 5.00 M | 50% ( 1.67 M) |
CYTK Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CYTK ranks across every disease it competes in
Competitive Position is a premium feature
See how CYTK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCYTK News
CYTKCytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
Cytokinetics has announced four upcoming presentations at the HFSA Annual Scientific Meeting 2026, including two Late Breaking Clinical Research presentations. These presentations will focus on the efficacy of Aficamten in treating non-obstructive hypertrophic cardiomyopathy. The meeting will take place in Phoenix, AZ from October 9 to 12, 2026. Cytokinetics continues to advance its pipeline of cardiac treatments.
Read more →CYTKCytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics has launched the ASPEN-HCM study to evaluate MYQORZO (aficamten) in patients with symptomatic obstructive hypertrophic cardiomyopathy. This multicenter, observational study aims to generate real-world evidence on the safety and effectiveness of MYQORZO over 12 to 36 months. The study will assess various clinical outcomes and healthcare resource utilization.
Read more →CYTKCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics announced the grant of stock options and restricted stock units to 23 new employees as an inducement to employment. The stock options have a 10-year term and will vest over four years, while the RSUs will vest over three years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to expanding its workforce in the biopharmaceutical sector.
Read more →CYTKCytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program
Cytokinetics has announced the ninth annual Communications Grant Program aimed at supporting patient advocacy organizations focused on hypertrophic cardiomyopathy and heart failure. The program will provide grants to enhance communication efforts and community engagement. Applications are open until October 2, 2026, with recipients announced in January 2027.
Read more →CYTKCytokinetics to Participate in September Investor Conferences
Cytokinetics, Inc. announced its participation in several investor conferences in September 2026, including the Citi BioPharma Conference and the Morgan Stanley Global Healthcare Conference. The management team will engage in fireside chats to discuss the company's advancements in cardiac muscle therapies. Cytokinetics is also preparing to submit a Supplemental New Drug Application for aficamten following positive Phase 3 trial results.
Read more →CYTKCytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026
Cytokinetics presented additional results from the ACACIA-HCM and MAPLE-HCM trials at the ESC Congress 2026. The findings indicate that aficamten significantly improves cardiac structure and diastolic function in patients with non-obstructive hypertrophic cardiomyopathy (HCM) and outperforms metoprolol in obstructive HCM. These results expand the evidence supporting aficamten's potential use across various HCM patient populations.
Read more →CYTK▼ -7.5%on this newsshared move
Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine
Cytokinetics announced positive results from the ACACIA-HCM trial, the first Phase 3 study to show significant improvements in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). The trial met its dual primary endpoints, leading the company to plan a supplemental New Drug Application to the FDA. The results were presented at the ESC Congress 2026 and published in The New England Journal of Medicine.
Read more →CYTKCytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
Cytokinetics has announced its participation in the European Society of Cardiology Congress 2026, featuring a Hot Line presentation on the ACACIA-HCM trial's positive results for aficamten in non-obstructive hypertrophic cardiomyopathy. The company will also host an investor event to discuss these findings. Presentations will take place from August 28-31 in Munich, Germany.
Read more →CYTK▼ -5.7%on this news
Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update
Cytokinetics reported a net product revenue of $25 million for MYQORZO in Q2 2026, indicating strong commercial momentum. The company plans to submit a Supplemental NDA for aficamten in non-obstructive HCM by Q4 2026, following positive results from the ACACIA-HCM trial. Additionally, Cytokinetics is expanding its market presence internationally, with launches in Germany and approvals in the UK.
Read more →CYTKCytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales
Cytokinetics has received marketing authorization from the MHRA for MYQORZO (aficamten) to treat symptomatic obstructive hypertrophic cardiomyopathy in the UK. Additionally, NICE has issued positive guidance for its use in eligible adult patients. The drug showed significant efficacy in improving peak oxygen uptake in clinical trials, although it is associated with some adverse reactions.
Read more →CYTKCytokinetics to Announce Second Quarter Results on August 6, 2026
Cytokinetics will announce its second quarter results on August 6, 2026, followed by a conference call to discuss financials and business updates. The company is recognized for its advancements in muscle biology and has a promising pipeline, including aficamten, which has shown positive results in clinical trials. The webcast of the call will be available for six months.
Read more →CYTKCytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026
Cytokinetics announced the acceptance of three Late Breaking Science abstracts for presentation at the ESC Congress 2026, highlighting positive results from the ACACIA-HCM trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy. The company will also host an investor event to discuss these findings. The presentations are scheduled for August 28-29, 2026, in Munich, Germany.
Read more →CYTK▼ -5%on this news
Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program
Cytokinetics has launched its annual Corporate Giving Program, which invites proposals from non-profit organizations aligned with its values. The program will focus on charitable donations aimed at supporting healthcare initiatives, science education, and essential services for local communities, particularly in the San Francisco Bay Area and Greater Philadelphia. Organizations can apply for donations up to $20,000, with the deadline for applications set for August 3, 2026.
Read more →CYTKCytokinetics Launches MYQORZO (aficamten) in European Union, with First Commercial Availability in Germany
Cytokinetics has launched MYQORZO (aficamten) in Germany, marking its first commercial entry into the European market for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This follows the European Commission's approval based on the positive outcomes of the SEQUOIA-HCM Phase 3 trial which demonstrated significant efficacy and safety. The company aims to broaden the availability of MYQORZO across Europe, reinforcing its commitment to patients suffering from this condition.
Read more →CYTKCytokinetics to Participate in June Investor Conferences
Cytokinetics announced its participation in two investor conferences in June 2026, including the Jefferies Global Healthcare Conference and the Goldman Sachs Global Healthcare Conference. The company will provide insights into its ongoing research and development efforts, particularly regarding its cardiac myosin inhibitors and activators. Additionally, Cytokinetics plans to present full results from a recent Phase 3 trial at a medical meeting.
Read more →CYTKCytokinetics to Hold Annual Meeting of Stockholders
Cytokinetics, Inc. announced the details of its upcoming Annual Meeting of Stockholders scheduled for May 27, 2026. The meeting will take place at the company's headquarters in South San Francisco, and stockholders of record are entitled to vote or attend. CEO Robert I. Blum will present an overview of the company's performance post-meeting. Cytokinetics is advancing multiple investigational medicines in cardiac muscle dysfunction, including MYQORZO® and omecamtiv mecarbil.
Read more →CYTKCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Cytokinetics, Inc. announced the grant of stock options and restricted stock units to eight employees as inducements under Nasdaq Listing Rule 5635(c)(4). These grants, amounting to 20,807 stock options and 13,793 RSUs, are designed to support the company's growth and attract talent. The RSUs will vest over three years while the stock options have a 10-year term. Cytokinetics continues to advance its pipeline, including the recently successful Phase 3 trial of aficamten for treating non-obstructive hypertrophic cardiomyopathy.
Read more →About Cytokinetics, Incorporated
Headquarters350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE PLUS
Trade the next CYTK catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime